Table 5. . Modeled health outcomes and costs – pegcetacoplan and comparators.
| Description | Pegcetacoplan | Eculizumab | Ravulizumab |
|---|---|---|---|
| Health outcomes | |||
| Life years | 19.06 | 19.06 | 19.06 |
| QALYs | 15.40 | 15.15 | 15.16 |
| Incremental for pegcetacoplan | – | 0.25 | 0.24 |
| Costs, $ | |||
| Drug cost | 8,730,068 | 9,711,310 | 8,816,420 |
| Incremental for pegcetacoplan | – | -981,242 | -86,352 |
| Supportive treatment | 157,734 | 157,734 | 157,734 |
| Incremental for pegcetacoplan | – | 0 | 0 |
| Administration cost | 135 | 84,551 | 27,338 |
| Incremental for pegcetacoplan | – | -84,416 | -27,203 |
| Vaccine cost | 462 | 174 | 174 |
| Incremental for pegcetacoplan | – | 288 | 288 |
| Health state costs | 8942 | 23,752 | 23,426 |
| Incremental for pegcetacoplan | – | -14,810 | -14,484 |
| Blood transfusion costs | 14,381 | 83,956 | 82,381 |
| Incremental for pegcetacoplan | – | -69,575 | -68,000 |
| Adverse events costs | 7210 | 34,262 | 24,521 |
| Incremental for pegcetacoplan | – | -27,052 | -17,311 |
| Total costs | 8,918,932 | 10,095,739 | 9,131,994 |
| Incremental total costs for pegcetacoplan | – | -1,176,808 | -213,062 |
Bold values indicate the total costs.
QALY: Quality-adjusted life year.